Chapter-11

ELISA: UNRAVELLING ITS FUNDAMENTALS AND DIVERSE APPLICATIONS

Gautam Panwar*
Assistant Professor, Glocal College of Paramedical Science and Research Centre, Glocal University, Saharanpur, U.P., India.

Ishita Verma
Assistant Professor, Department of Medical Laboratory Technology, CT University, Ludhiana, Punjab, India.

Ashrita Dubey
Assistant Professor, Glocal College of Paramedical Science and Research Centre, Glocal University, Saharanpur, U.P., India.

***Correspondence to:** gautampnwr3@gmail.com*

***DOI:** https://doi.org/10.52458/9789388996846.nsp2023.eb.ch-11*
Ch.Id:-GU/NSP/EB/CMDT/2023/Ch-11

ABSTRACT

The Enzyme-Linked Immunosorbent Assay (ELISA) is a powerful biochemical technique used for detecting and quantifying specific proteins, antibodies, antigens, and biomolecules. ELISA's development in the early 1970s represented a significant advancement in immunoassays, eliminating the need for radioactive materials. This article provides an overview of ELISA, discussing its principles, materials, methods, and applications. Recent advances and challenges in ELISA are also explored, highlighting its enduring importance in research, clinical diagnostics, and drug development

Keywords: *ELISA, Enzyme-Linked Immunosorbent Assay, Antibody-Antigen Interaction, Immunoassay, Diagnostic Test.*

11.1 INTRODUCTION TO ELISA

Enzyme-Linked Immunosorbent Assay, commonly known as ELISA, is a powerful and versatile biochemical technique used for the detection and quantification of specific proteins, antibodies, antigens, and other biomolecules. It has become a cornerstone in various fields, including immunology, molecular biology, clinical diagnostics, and pharmaceutical research. ELISA's popularity stems from its high sensitivity, specificity, and ease of use, making it an indispensable tool for researchers and healthcare professionals alike (Bonifacino, J. S., & Dasso, M. 2005).

11.2 HISTORICAL BACKGROUND

The origins of ELISA can be traced back to the early 1970s when Swedish immunologist Peter Perlmann and Eva Engvall, along with American scientist Robert L. Fenner, independently developed the assay. Their work built upon the principles of radioimmunoassay (RIA) and enzyme labeling techniques, culminating in the creation of a novel and safer method for detecting and quantifying biological molecules. ELISA's development represented a significant advancement in the field of immunoassays, as it eliminated the need for radioactive materials and made the technique more accessible to laboratories worldwide.

11.3 BASIC PRINCIPLES OF ANTIGEN-ANTIBODY INTERACTION

At the core of ELISA lies the specific interaction between antigens and antibodies. This interaction is central to the assay's functionality (Hulst, A., et al.2000). Here are the basic principles:

1. **Antigen-Antibody Binding:** ELISA relies on the high specificity of antibodies for their target antigens. When a sample containing the antigen of interest is added to

a solid surface (often a microtiter plate) coated with a capture antibody, the antigen binds to the antibody with high affinity. This forms an antigen-antibody complex on the plate.

2. **Washing and Removal of Unbound Molecules:** After allowing time for binding, unbound molecules are removed by thorough washing. This step is crucial to minimize background noise and ensure assay accuracy.
3. **Detection:** A detection antibody, which is linked to an enzyme (e.g., horseradish peroxidase or alkaline phosphatase), is added. This detection antibody recognizes a different epitope on the bound antigen, allowing for a sandwich-like complex formation (in sandwich ELISA).
4. **Substrate Addition:** A substrate solution that is specific to the enzyme is added. In the presence of the enzyme, the substrate undergoes a chemical reaction that results in a colour change (in colorimetric assays), fluorescence (in fluorescent assays), or luminescence (in chemiluminescent assays).
5. **Measurement:** The intensity of the resulting signal (e.g., absorbance, fluorescence, or luminescence) is directly proportional to the amount of the antigen in the sample. By comparing this signal to a standard curve generated from known concentrations of the antigen, the sample's concentration can be determined.

11.4 TYPES OF ELISA

1. **Direct ELISA:** Direct ELISA is a straightforward method used for the detection of antigens. It relies on the direct binding of a labeled antibody to the target antigen. ***Figure 11.1 depicts the scmematic presentation of types of ELISA.***
2. **Indirect ELISA:** Indirect ELISA provides greater sensitivity by using an unlabeled primary antibody and a labeled secondary antibody.
3. **Sandwich ELISA:** Sandwich ELISA is used for the detection and quantification of specific antigens. It is highly specific and suitable for complex samples.
4. **Competitive ELISA:** Competitive ELISA measures the competition between labeled and unlabeled antigens or antibodies for binding to capture antibodies.

Each type of ELISA has its advantages and is chosen based on the specific needs of the assay, including sensitivity, specificity, and the type of target molecule being detected (Nelson, L. D., & Johnson, R. 1980). Researchers select the appropriate ELISA format based on the characteristics of their samples and the desired outcome of the assay.

11.5 REAGENTS AND EQUIPMENT REQUIRED

Performing an ELISA assay requires a set of specific reagents and equipment (Wu, A. H. 2002). Here is a list of essential components:

Reagents:

1. **Antigens and Antibodies:** Depending on the type of ELISA, you will need capture antibodies, detection antibodies, and antigens specific to your target of interest.



Figure-11.1: Schematic presentation of basic types of ELISA: a direct, b indirect, c sandwich, d competitive (Adopted from Boguszewska et al. 2019)

2. **Blocking Agents:** Typically, blocking agents like bovine serum albumin (BSA) or milk proteins are used to minimize non-specific binding to the plate.
3. **Washing Buffers:** Buffer solutions (e.g., phosphate-buffered saline with Tween 20, PBS-T) for washing and removing unbound molecules.
4. **Substrate:** Enzyme-specific substrates for generating a detectable signal (e.g., 3,3',5,5'-Tetramethylbenzidine, TMB, for HRP).
5. **Standard Samples:** Known concentrations of the analyte of interest to generate standard curves for quantification.

Equipment:

1. **Microtiter Plate:** 96-well or 384-well plates, coated or uncoated, for immobilizing antibodies and antigens.
2. **Plate Reader:** A microplate reader capable of measuring absorbance, fluorescence, or luminescence.
3. **Pipettes and Tips:** Pipettes with appropriate volume ranges for accurate sample and reagent dispensing.
4. **Incubator:** To control temperature during the assay, typically set to 37°C.
5. **Microplate** Washer: For automated washing of the plate wells.
6. **Plate Shaker:** To ensure thorough mixing of reagents during incubation steps (Selvaraju, S. B., & Selvarangan, R. 2016).

11.6 PROTOCOL FOR PERFORMING ELISA

Here is a general step-by-step guide on how to perform an ELISA:

1. **Coating:**
    - Coat the wells of a microtiter plate with capture antibodies or antigens specific to your target.
    - Incubate the plate to allow immobilization.
    - Block the unoccupied binding sites to prevent non-specific binding.
2. **Sample Preparation:**
    - Prepare your samples (e.g., serum, plasma, cell lysate) and standards.

- Dilute samples as needed in a sample dilution buffer.

3. **Sample Application:**
    - Add the prepared samples and standards to the appropriate wells of the coated plate.
4. **Incubation:**
    - Incubate the plate at a controlled temperature for a specified period to allow binding between antigens and antibodies.
5. **Washing:**
    - Wash the plate multiple times with a washing buffer to remove unbound substances.
6. **Secondary Antibody or Detection Reagent:**
    - Add a labeled secondary antibody or detection reagent that recognizes the bound target antigen or antibody.
7. **Incubation:** Incubate the plate again to allow the secondary antibody or detection reagent to bind.
8. **Washing:** Wash the plate to remove unbound secondary antibodies or detection reagents.
9. **Substrate Addition:**
    - Add the substrate specific to the enzyme label (e.g., TMB for HRP).
    - Incubate the plate to allow the enzymatic reaction to occur.
10. **Signal Measurement:** Measure the signal generated by the enzymatic reaction (e.g., absorbance, fluorescence, or luminescence) using a microplate reader.
11. **Data Analysis:**
    - Construct a standard curve using the known concentrations of standards.
    - Calculate the concentration of the target analyte in samples based on the standard curve (Christodoulides, N., et al. 2002).

11.7 DETECTION SYSTEMS

- **Enzyme Labels and Substrates:** Enzymes like Horseradish Peroxidase (HRP) and Alkaline Phosphatase (AP) are commonly used as labels in ELISA. These enzymes catalyze reactions with specific substrates, resulting in a detectable signal. For example, HRP can catalyze the conversion of TMB to a blue color in a colorimetric assay.

- **Fluorescent and Chemiluminescent Detection:** In addition to enzymatic labels, fluorescent and chemiluminescent labels are used for ELISA detection. These systems offer enhanced sensitivity and are often employed in applications where quantification at lower concentrations is necessary (Wang, C. H., & Lien, K. Y. 2011). Fluorescence detection relies on the emission of fluorescent light upon excitation, while chemiluminescence uses a chemical reaction to produce light without external excitation.

- **Colorimetric Detection:** Colorimetric detection methods rely on changes in color as a result of enzymatic reactions. For example, in a colorimetric ELISA, the enzymatic reaction produces a color change, which can be measured spectrophotometrically. The intensity of the color is proportional to the concentration of the target analyte (Bange, A. et al, 2005).

11.8 QUANTIFICATION AND DATA ANALYSIS

- **Standard Curves and Calibration:** To quantify the concentration of the target analyte in samples, a standard curve is constructed using known concentrations of standards (Lopez, M. F. et al, 2013). The standard curve represents the relationship between signal intensity (e.g., absorbance, fluorescence, or luminescence) and analyte concentration. By comparing the signal of samples to the standard curve, the concentration of the analyte in the samples can be determined.

- **Calculation of Sample Concentrations:** The concentration of analytes in samples is calculated based on their signal intensities and the standard curve. The specific formula for calculating sample concentrations depends on the type of standard curve (linear or non-linear) and the units used for reporting concentrations.

- **Statistical Analysis of ELISA Data:** Statistical analysis can be applied to ELISA data to assess assay reliability and detect outliers or anomalies. Common statistical methods include calculating mean values, standard deviations, and coefficients of variation. Additionally, statistical tests such as t-tests or ANOVA can be used to compare data from different groups or conditions, providing insights into the significance of differences observed in the ELISA results.

11.9 APPLICATIONS OF ELISA

- **Clinical Diagnostics:** ELISA is widely employed in clinical diagnostics for detecting a variety of diseases and conditions. Notable examples include HIV, COVID-19, and cancer markers. ELISA tests are valuable tools for early disease detection and monitoring of patients' response to treatment.
- **Research Applications:** In research, ELISA is used for a multitude of purposes, including quantifying proteins, detecting specific antibodies in serum, and identifying biomarkers associated with various diseases. ELISA plays a vital role in drug development, vaccine research, and understanding disease mechanisms.
- **Pharmaceutical and Biotechnology Industry:** Pharmaceutical companies use ELISA for drug development and quality control. ELISA assays are employed in pharmacokinetic studies to determine the concentration of drugs in blood and assess their efficacy and safety profiles. ELISA's versatility and sensitivity have established it as a cornerstone technique in various scientific disciplines, contributing significantly to advancements in healthcare, biotechnology, and fundamental research.

11.10 RECENT ADVANCES IN ELISA

- **High-Throughput ELISA:** High-throughput ELISA systems have revolutionized the efficiency and applications of ELISA assays. These systems allow for the simultaneous analysis of a large number of samples, significantly reducing assay time and labor (Anderson, N. L., & Anderson, N. G. 2002). Main advancements in high-throughput ELISA include:
- **Automation:** Robotic systems and liquid handling devices automate the entire ELISA process, from sample handling to data analysis, making it suitable for high-throughput screening.
- **Multi-Mode Plate Readers:** Advanced plate readers can rapidly measure multiple samples at once, reducing the time required for signal detection.
- **Array Formats:** Microarrays, where multiple antibodies or antigens are spotted onto a single chip, enable the screening of hundreds or thousands of analytes in parallel.

- High-throughput ELISA systems find applications in drug discovery, clinical diagnostics, and biomarker screening, where rapid analysis of large sample sets is essential.
- **Multiplex ELISA:** Multiplex ELISA, also known as multiplex immunoassays, allows the simultaneous detection of multiple analytes within a single sample. This technology has gained prominence due to its ability to provide comprehensive and highly informative data in a single assay (Abdallah, H., et al., 2021) Key aspects of multiplex ELISA include:
- **Microbead-Based Assays:** Microbeads coated with different capture antibodies for various analytes are mixed in a single reaction, allowing the simultaneous measurement of multiple targets.
- **Luminex Technology:** Luminex-based multiplex assays use fluorescently labeled microspheres to distinguish between different analytes, making it possible to detect up to hundreds of targets simultaneously.
- Multiplex ELISA is widely used in cytokine profiling, cancer biomarker panels, and autoimmune disease diagnostics, offering a more efficient and cost-effective approach compared to running multiple single-analyte ELISAs (Roda, A., et al., 2014).
- **Microfluidic ELISA:** Microfluidic devices have brought miniaturization and automation to ELISA assays. These microscale systems offer several advantages, including reduced reagent consumption, shorter assay times, and precise control over fluid handling (Iakovlev, A. P. et. al., 2022). Key features of microfluidic ELISA include:
- **Lab-on-a-Chip Technology:** Microfluidic chips integrate all aspects of ELISA, from sample preparation to detection, on a single microchip, reducing the need for manual intervention.
- **Enhanced Sensitivity:** Microfluidic systems can achieve higher sensitivity by efficiently mixing samples and reagents within microchannels.
- Microfluidic ELISA is especially valuable for point-of-care testing, where rapid and sensitive assays are needed, and for resource-limited settings due to its small sample volume requirements.

11.11 LIMITATIONS OF ELISA

Despite its widespread use, ELISA has certain limitations:

- **Limited Multiplexing:** Traditional ELISA is limited in terms of the number of analytes that can be simultaneously detected in a single assay
- **Matrix Effects:** Complex sample matrices, such as serum or plasma, can interfere with ELISA assays, leading to false positives or false negatives.

11.12 CONCLUSION

In conclusion, ELISA remains a foundational and indispensable tool in modern scientific and medical research. Recent advancements in high-throughput, multiplex, and microfluidic ELISA have enhanced its efficiency and expanded its applications. While ELISA has its limitations, emerging technologies and alternative methods are poised to address these challenges, offering a promising future for this versatile assay. Its enduring importance in biomarker discovery, clinical diagnostics, drug development, and research continues to drive innovation and further establish its role in advancing healthcare and scientific knowledge.

REFERENCES

1. *Abdallah, H., et al. (2021). Challenges and opportunities in multiplexed ELISA assays: A review. Journal of Immunological Methods, 490, 112999.*
2. *Anderson, N. L., & Anderson, N. G. (2002). The human plasma proteome: history, character, and diagnostic prospects. Molecular & Cellular Proteomics, 1(11), 845-867.*
3. *Bange, A., Halsall, H. B., & Heineman, W. R. (2005). Microfluidic immunosensor systems. Biosensors and Bioelectronics, 20(12), 2488-2503.*
4. *Boguszewska, Karolina & Szewczuk, Michał & Urbaniak, Sandra & Karwowski, Boleslaw. (2019). Review: immunoassays in DNA damage and instability detection. Cellular and Molecular Life Sciences. 76. 10.1007/s00018-019-03239-6.*
5. *Bonifacino, J. S., & Dasso, M. (2005). Introduction to ELISA. Current Protocols in Cell Biology, 1-6.*
6. *Christodoulides, N., Tran, M., Floriano, P. N., Rodriguez, M., Goodey, A., Ali, M. F., ... & McDevitt, J. T. (2002). A microchip-based multianalyte assay system for the assessment of cardiac risk. Analytical Chemistry, 74(12), 3030-3036.*

7. *Hulst, A. G., van der Heijden, R., & Savelkoul, H. F. (2000). Immunoassays – state of the art. Methods, 22(1), 9-21.*
8. *Iakovlev, A. P., Erofeev, A. S., & Gorelkin, P. V. (2022). Novel Pumping Methods for Microfluidic Devices: A Comprehensive Review. Biosensors, 12(11), 956. https://doi.org/10.3390/bios12110956*
9. *Lopez, M. F., Sarracino, D. A., Prakash, A., Athanas, M., & Krastins, B. (2013). Reagent proteomics: 3D protein maps of signaling complexes using immobilized antibody arrays and mass spectrometry. Expert Review of Proteomics, 10(1), 77-90.*
10. *Nelson, L. D., & Johnson, R. (1980). Enzyme-linked immunosorbent assay (ELISA). Methods in Enzymology, 70, 436-443.*
11. *Roda, A., Michelini, E., Cevenini, L., & Calabria, D. (2014). Recent developments in rapid multiplexed bioanalytical methods for foodborne pathogenic bacteria detection. Microchimica Acta, 181(8-9), 705-718.*
12. *Selvaraju, S. B., & Selvarangan, R. (2016). Evaluation of three analyte-specific reagents for detection of adenovirus by the Luminex xTAG respiratory viral panel assay. Journal of Clinical Microbiology, 54(3), 767-772.*
13. *Wang, C. H., & Lien, K. Y. (2011). Recent advances in microfluidic immunoassays for clinical applications. Electrophoresis, 32(22), 2454-2466.*
14. *Wu, A. H. (2002). A selected history and future of immunoassay development and applications in clinical chemistry. Clinica Chimica Acta, 327(1-2), 1-9.*